1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
Loading...
Loading...
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Capital Structure
3. What does Kardigan, Inc. do?
4. Valuation
5. Business & Product Moat
6. People & Governance
7. Financial Quality
8. 𝕏 Posts
Discussion
Symbol
KARD
Event Date
2026-06-18
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
—
Shares Offered
23.33M
Shares Outstanding Pre-IPO
16.58M
87.67M
—
Implied Upside vs Midpoint
$00.00Description
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale. Our management team includes leaders from MyoKardia, Inc. (“MyoKardia”) with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy. Cardiovascular disease is the leading cause of death worldwide, yet innovation has lagged due to drug development focused on broad, downstream, symptom-focused approaches despite disease heterogeneity and genetic variability, resulting in incremental advances and lengthy clinical trials. Kardigan is committed to overcoming these challenges by advancing precision medicines that target the fundamental drivers of cardiovascular conditions, aiming to deliver meaningful improvements in patient outcomes. --- We were incorporated under the laws of the State of Delaware in August 2023 under the name EnCarda, Inc., and changed our name to Kardigan, Inc. in December 2024. Our principal executive offices are located at 506 Carnegie Center Drive, Suite 201, Princeton, NJ 08540, and our telephone number is (415) 573-3220. We have two subsidiaries, Rancho Santa Fe Bio, Inc., formed in October 2019 under the laws of the State of Delaware, and Prolaio, Inc., formed in November 2021 under the laws of the State of Delaware. Our website address is www.kardigan.bio.
○
No current product revenues; value hinges on pipeline clinical outcomes○
Three lead candidates: Danicamtiv, Ataciguat, Tonlamarsen○
Prolaio is positioned as a trial-enabling platform; value depends on real-world validation in pivotal designsPost-IPO economic shares by class.
| Class | Shares | % Economic |
|---|---|---|
Voting Common Stock (Common stock) (listed) 1 vote per share (typical for common stock) | 87.67M | 100.0% |
| Total economic shares | 87.67M | 100% |
Redeemable Convertible Preferred Stock Pre-conversion — already in the listed class | 29.99M |
Kardigan’s IPO valuation prices in meaningful clinical de-risking across a concentrated late‑stage cardiovascular pipeline, with outcomes likely dominated by Phase 2b toplines and subsequent Phase 3 execution rather than any near‑term cash generation. With no approved products and outsized near‑term burn, the stock sets up as a high‑beta clinical readout vehicle: wins can re-rate quickly, but any material trial miss or funding pressure can impair equity value.
The next 12–36 months hinge on Phase 2b topline readouts for Danicamtiv and Tonlamarsen, Phase 2b/interim and topline events for Ataciguat, and early proof that the Prolaio trial‑enabling platform can improve pivotal design and patient selection. Management expects IPO proceeds to fund pivotal activities through 2028, making upcoming readouts and Phase 3 starts the key checkpoints for institutional re‑underwriting.
Kardigan is pre‑revenue and operating as a scaled R&D organization (FY2025 opex ~$201.8M vs FY2024 ~$96.7M), so losses are structurally tied to trial pace and scope. If programs succeed, the model can shift toward specialty‑biopharma economics, but commercialization timing and ultimate pricing/reimbursement for RNA/precision cardio therapies remain the swing factors.
The CEO’s MyoKardia track record and an experienced clinical development bench support execution credibility, but reliance on a small set of known leaders remains high given limited disclosure depth on some directors/executives. Key operational risks are manufacturing and regulatory complexity for RNA/oligonucleotide modalities and the practical challenge of embedding Prolaio into pivotal trials in a way regulators and payers ultimately accept.
Bull case: clean Phase 2b toplines plus rapid Phase 3 starts, with Prolaio showing measurable trial‑design lift, drives a re‑rate toward established cardio/RNA comps and raises strategic interest. Base case: incremental or mixed data sustains a clinical‑stage multiple with a longer, stepwise de‑risking path. Bear case: failed readouts, inability to validate Prolaio, or a tighter funding window forces dilution and a sharp valuation reset.
+
Experienced leadership with demonstrated prior success in cardio biotech−
Binary risk profile tied to pivotal trial readouts and platform validation○
Targets underserved cardiovascular indications with late-stage pipeline○
Prolaio may improve patient selection and trial efficiency if validated in pivotal settings○
Value creation is milestone-driven, with sharp re-rating potential on clean data+
Upside contingent on Phase 2b/3 data, regulatory progress, and commercial adoption−
Valuation is driven by late-stage pipeline and platform potential with binary risk+
CEO/co-founder Tassos Gianakakos: prior MyoKardia CEO, strong biotech track record○
CFO Brianne Puglisi: prior senior finance roles in public biotech and BD○
Chief Medical Officer Jay Edelberg, M.D., Ph.D.: R&D and scientific leadership○
Execution remains key-person dependent given the late-stage, milestone-driven plan−
Net loss expanded from $88.7M (2024) to $191.9M (2025), reflecting development scale-up○
No product revenue; clinical-stage with high R&D expense ($153M in 2025)○
Cash balance increased to $109M at FY2025 end; $81.5M as of Q1 2026○
Operating expenses rose to ~$201.8M in 2025 from ~$96.7M in 2024 as development scaledMostly deal/launch-style commentary with limited discussion of Kardigan’s clinical differentiation, so the posts don’t add a clear directional view on the pipeline.
AI per-post analysis: 1 positive, 0 negative, 2 neutral (engagement-weighted aggregate).